相关实验视频

Updated: Jun 28, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

乳糖菌 (Lacticaseibacillus) 和菌 (Paracasei) BNCC345679彻底改变了DSS诱导的大肠炎,并调节了肠道微生物群

Waqar Ahmad¹, Ahmad Ud Din^1,2, Taj Malook Khan¹

¹Basic Medicine Research Innovation Centre for Cardiometabolic Diseases, Ministry of Education, Southwest Medical University, Luzhou, China.

Frontiers in microbiology

|April 11, 2024

概括

乳酸菌cillus paracasei BNCC345679有效地减轻了小鼠的德克斯硫酸诱导的大肠炎. 这种益生菌恢复了肠道微生物群的平衡,减少了炎症,增强了肠道屏障功能,显示了炎症性肠道疾病管理的潜力.

科学领域:

微生物学微生物学
免疫学免疫学免疫学
胃肠病学胃肠病学

背景情况:

炎症性肠病 (IBD) 的进展受到肠道微生物群组成的显著影响.
益生菌对IBD有治疗前景,但它们对肠道微生物组和肠炎模型中的免疫调节的特定影响需要进一步研究.

研究的目的:

在大肠炎的小鼠模型中评估Lacticaseibacillus paracasei BNCC345679的治疗潜力.
调查L. paracasei BNCC345679对肠道微生物组失调,炎症标志物,氧化应激和肠道屏障功能的影响.

主要方法:

将L. paracasei BNCC345679给患有德克斯硫酸盐 (DSS) 诱导的大肠炎的小鼠.
对肠道微生物群组成,炎症性细胞因子,微RNA (miRNA),VCAM-1表达,氧化应激标志物和肠道完整性蛋白质 (MUC2,ZO-1) 的分析.

主要成果:

口服L. paracasei BNCC345679的干预促进了有益细菌的恢复,包括乳酸菌和Akkermansia物种.
治疗导致体重,疾病活动指数 (DAI) 得分的改善,并降低了促炎性细胞因子的水平.
L. paracasei BNCC345679减轻了氧化应激,并增强了肠道屏障蛋白MUC2和ZO-1的表达.

结论:

L. paracasei BNCC345679在减少DSS诱导的大肠炎方面表现出显著的治疗能力.
这种益生菌通过恢复肠道平衡和屏障功能来表现出作为管理炎症性肠病的补充剂的潜力.

关键词:

DSS引起的结肠炎乳酸酶ibacillus paracasei BNCC345679 这是一个非常好的方法.这种疾病叫做dysbiosis.肠道炎症肠道炎症我们的肠道微生物群.这是一个微型RNA.益生菌是一种益生菌.

更多相关视频

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

相关概念视频

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...